We accelerate lifesaving research by modernizing how clinical and translational science is funded — so institutions can move proof-of-concept programs forward when traditional grant timelines and budgets fall short.
BioCrowd accelerates lifesaving research by modernizing how clinical and translational science is funded — so institutions can move proof-of-concept programs forward when traditional grant timelines and budgets fall short.
Research institutions are facing growing funding uncertainty and longer cycles to secure capital. BioCrowd provides clinical research funding infrastructure that helps hospitals, universities, and patient foundations launch milestone-based campaigns supported by donor-advised funds, venture philanthropy, and impact-aligned capital.
BioCrowd is led by experienced operators across healthcare, biotech, finance, and technology — with deep experience in academic research ecosystems and commercialization pathways. We combine institutional rigor with modern funding rails to help science reach patients faster.
30+ years across enterprise technology and blockchain, including Accenture and PwC experience, and leadership across large-scale digital initiatives. Mark focuses on institutional strategy.
Cancer researcher with experience across rare disease networks and applied AI in biomedical contexts. Solenn leads scientific diligence, project selection, and translational strategy.
Executive Director and Head of Molecular Epidemiology & Clinical Data Sciences at Gilead; former CDC senior advisor. Shahed supports clinical credibility, evidence strategy, and real-world data alignment.
Product and engineering leader with experience across GenAI/ML and platform development. Srini leads BioCrowd's product execution, security, and scalable infrastructure.
Experience in financial modeling, venture finance strategy, and digital asset markets. Angelo supports campaign financial structures and institutional-grade analytics.
Serial entrepreneur and investor with decades of experience across IT and healthcare, including multiple successful exits. John advises on company strategy, scaling, and enterprise partnerships.
15+ years bridging academia and biopharma, including senior roles at Institut Curie and Institut Carnot CALYM. Emmanuel supports academic-to-industry partnership strategy and commercialization pathways.
Healthcare executive leading innovations in care delivery, with leadership experience across major clinical organizations. Prentice advises on health system alignment, adoption, and clinical operations.
Scientist with 10+ years across biotech/pharma and academia (including J&J, Scripps, UCSF). Cristina supports BioCrowd's research evaluation approach and translational readiness assessment.
| What Sets Us Apart | What It Means |
|---|---|
| Institution-First, Not Protocol-First | We start with your strategic priorities, not pre-designed protocols. Our approach ensures alignment with your mission and ongoing initiatives. |
| Tailored Proof-of-Concept (POC) | We co-develop a POC project that reflects your institution's real-world needs — whether for translational research, clinical trial coordination, or public-private collaboration. |
| Bridge Between Academic Rigor & Emerging Technologies | We help you explore new funding models (Web3, blockchain, DAOs) without compromising academic standards or compliance. |
| Smart Partnering, Not Just Smart Contracts | Our model encourages collaborative governance with your teams, embedding stakeholder insights into every phase. |
| Visibility & Credibility | We support early-stage projects not only with funding, but also with exposure to international partners, press visibility, and academic validation. |
| Built by Researchers, for Researchers | We're not here to sell a tool — we're here to co-create a catalyst. Let's build something together that advances your institution's impact and inspires future models of research. |